COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Participating in August 25-26 Animal Health Summit with Goal of Securing Collaboration to Expand Canalevia's Indication to Treatment of General Diarrhea in Dogs
Jaguar Health announces conditional FDA approval of Canalevia-CA1 for CID in dogs and strategic plans to expand indication for general diarrhea treatment globally. Participation in 2025 Animal Health Summit -
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Family Company Napo Pharmaceuticals to Meet with FDA to Discuss Potential Regulatory Pathways for Crofelemer for Treatment of Ultrarare Pediatric Indication Microvillus Inclusion Disease (MVID)
Napo Pharmaceuticals plans FDA meeting to discuss crofelemer clinical program for MVID, with proof-of-concept results reducing TPN. Abstract accepted for NASPGHAN 2025 Annual Meeting in Chicago
